BiotechTube
OrsoBio

OrsoBio

Palo Alto, United States· Est.
orsobio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $197M

Overview

OrsoBio is a private, clinical-stage biotech focused on novel small molecule therapies for severe metabolic diseases, aiming to restore energy homeostasis. Its pipeline includes programs like TLC-2716, an LXR inverse agonist in Phase 2a for hypertriglyceridemia and metabolic liver disease, and TLC-1180, a protonophore being explored for obesity. The company is backed by a seasoned leadership team and notable venture capital firms, having raised significant funding, including a $67M round in 2024.

Metabolic DiseasesLiver DiseasesObesityDiabetesDyslipidemias

Technology Platform

Focus on restoring energy homeostasis by targeting fundamental pathways of cellular energy metabolism, including mechanisms like LXR inverse agonism and mitochondrial protonophore activity.

Funding History

4
Total raised:$197M
Venture$67M
Series A$60M
Series A$60M
Seed$10M

Opportunities

The global epidemics of obesity, diabetes, and MASH represent multi-billion dollar markets with significant unmet need, especially for disease-modifying therapies.
The success of GLP-1 agonists has validated the space and created demand for novel mechanisms and combination approaches, which aligns with OrsoBio's pipeline strategy.

Risk Factors

High clinical development risk as novel mechanisms must prove safe and effective in later-stage trials.
Intense competition from large pharma and well-funded biotechs in the metabolic disease space.
Dependence on future fundraising to advance the pipeline, given its pre-revenue status.

Competitive Landscape

OrsoBio competes in the crowded and fast-moving metabolic disease arena, facing large players like Novo Nordisk, Eli Lilly, and Pfizer, as well as numerous biotechs. Its differentiation hinges on its first-in-class mechanisms targeting energy homeostasis, but it must demonstrate superior efficacy or safety profiles to gain market share.

More companies in Small Molecule Drugs →More companies in United States →